What's Hot at AHA22? Top 10 Late-breaking Science Trials

Stay updated on the AHA 22 late-breaking data!

In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions. 

• What are the key take-aways from AHA 22?
• What are the most promising findings?
• How should we understand the new data in the context of patient care?

Agenda

• ISCHEMIA-EXTENDed: Follow-Up Interim Report
• TRANSFORM-HF: Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure
• IRONMAN: Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure with Reduced Ejection Fraction
• ECMO-CS: Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock
• RESPECT-EPA: Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid
• PRECISION: Sustained Blood Pressure Lowering Effect with the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results from a Randomized, Controlled Study Including a Withdrawal Phase
• BrigHTN: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Treatment-Resistant Hypertension
• SPYRAL HTN-ON: Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs
• EARLY-AF: Early Aggressive Invasive Intervention for Atrial Fibrillation
• DOSE VF: Double Sequential External Defibrillation for Refractory Ventricular Fibrillation

For our full AHA 22 coverage click here.